Gastro-oesophageal junction cancer.
A plain-language guide to cancer at the junction of the oesophagus and stomach: the Siewert types, why the distinction matters, and how it is diagnosed and treated in Australia.
What GOJ cancer is.
The gastro-oesophageal junction (GOJ) is the point where the food pipe meets the stomach. Cancers that start at or across this boundary are called GOJ cancers, or junctional cancers.
They are classified by where the centre of the tumour sits, using the Siewert system. Type I tumours are centred 1 to 5 cm above the junction and behave like oesophageal cancer. Type II tumours are centred between 1 cm above and 2 cm below the junction. Type III tumours are centred 2 to 5 cm below the junction and behave like stomach cancer.
The type matters because it determines the operation, the chemotherapy or radiotherapy plan, and even how the cancer is staged. Under the current staging system, a junctional tumour whose centre is no more than 2 cm into the stomach is staged as oesophageal cancer, and beyond 2 cm it is staged as gastric cancer.
GOJ cancer is increasingly recognised as its own entity. Research shows it can behave differently from both oesophageal and gastric cancer, and trials often group it with one or the other, which is why the evidence base is less certain than for either cancer alone.
Australian national statistics do not report GOJ cancer separately. The oesophageal and stomach figures include junctional tumours under their own codes, so a national GOJ count is not published.
What raises the risk.
Type I and type II tumours share the risk profile of oesophageal adenocarcinoma: long-standing acid reflux, Barrett's oesophagus and excess body weight. Smoking and alcohol add risk, particularly for squamous tumours further up the oesophagus.
Type III tumours share the risk profile of stomach cancer, including Helicobacter pylori infection, smoking and a diet high in salt-preserved foods.
Most people with reflux or Barrett's never develop cancer. Barrett's carries a lifetime risk of oesophageal adenocarcinoma of roughly 3 to 13 in 100, and an annual risk below 1 in 100, which is why surveillance intervals are individualised rather than universal.
There is no national screening program for GOJ cancer. Testing is prompted by symptoms, or by surveillance if you have Barrett's oesophagus.
Reflux that changes is the signal. New difficulty swallowing, food sticking, or reflux that no longer responds to treatment should be assessed promptly.
Symptoms worth taking to a GP.
Early GOJ cancer often causes no symptoms. When it does, they usually relate to swallowing or to the stomach emptying slowly.
Food sticking or difficulty swallowing
The most common and most important symptom. It usually means the passage is narrowing and needs urgent investigation.
Pain or burning on swallowing
A burning or sharp sensation behind the breastbone, sometimes mistaken for reflux.
Feeling full quickly or nausea
Food may sit in the stomach, causing early fullness, bloating or vomiting.
Unexplained weight loss
Often follows reduced eating, but can occur independently.
Upper abdominal or chest discomfort
Persistent pain or pressure with eating.
New or worsening heartburn
Reflux that has changed in pattern, frequency or response to treatment.
Vomiting blood or black stools
Seek urgent care. Slow bleeding may show up as anaemia and tiredness.
Difficulty swallowing is the symptom not to wait on. It has many causes, but it needs a camera test rather than a trial of medication.
How it is diagnosed.
Diagnosis follows the same path as oesophageal and stomach cancer: camera, biopsy, imaging, then a team decision.
From referral to a treatment plan
Because the type changes the plan, ask your team to tell you the Siewert type and the stage in writing, so you can explain it to family and to your GP.
What treatment looks like.
Type I and type II
These are generally managed along the oesophageal pathway. For locally advanced tumours, treatment before surgery usually means perioperative chemotherapy or chemoradiotherapy, followed by an oesophagectomy. For adenocarcinoma, a randomised trial comparing the two strategies found better survival with perioperative chemotherapy than with chemoradiotherapy. The best approach for type II tumours is still debated, so ask your team why one was chosen for you.
Surgery removes the lower oesophagus and the top of the stomach, with nearby lymph nodes, and rejoins the remaining stomach to the oesophagus.
Type III
These are managed along the gastric pathway, typically with perioperative chemotherapy (FLOT) and an extended gastrectomy that includes the lower oesophagus if needed, with lymph node removal.
Advanced cancer
When the cancer has spread, treatment aims to control symptoms and extend good-quality time. Options include chemotherapy, immunotherapy in selected cases, radiotherapy to a painful or bleeding area, and stenting or a feeding tube to keep the passage open.
Palliative care works alongside active treatment to manage pain, nausea, nutrition and fatigue. Advance care planning, which records what matters to you and who can speak for you, can start at any stage.
Nutrition
Eating is affected by the tumour and by surgery. Dietitian support should start before treatment, and some people need temporary feeding through a tube.
Clinical trials
Trials usually group GOJ cancer with oesophageal or gastric cancer, which is why GOJ-specific evidence is limited. Ask whether a trial is open to you.
The Siewert type is the key decision point. Ask why your tumour is being treated along the oesophageal or the gastric pathway, and what that means for surgery and chemotherapy.
The research we fund.
HOPE Fund projects support recovery and decision-making for people having major surgery at the junction of the oesophagus and stomach.
HIIT Cancer
A randomised trial of high-intensity interval training started immediately after major foregut surgery, testing whether early structured exercise improves recovery.
Muscle, weight and treatment
A study measuring body composition before, during and after treatment for stomach and oesophageal cancer, including junctional tumours.
Plain-language patient guides
Understanding the plan makes it easier to cope with it.
A family who lived it.
Ken Whittle was diagnosed with a junctional cancer after a sudden health scare. He speaks about the diagnosis, the care he received and the resilience that carried him through treatment.
His story is one person's experience, not a prediction for anyone else.
Questions people actually ask.
What does Siewert type mean?
It describes where the centre of the tumour sits relative to the junction: type I above it, type II at it, type III below it. The type decides whether the cancer is treated like oesophageal or stomach cancer.
Why is my cancer called oesophageal when it is at the junction?
Staging classifies a junctional tumour as oesophageal if its centre is no more than 2 cm into the stomach, and as gastric if it is further down. That rule keeps staging consistent with how the cancer behaves.
Is there a separate GOJ statistic for Australia?
No. National statistics report oesophageal and stomach cancers separately, and junctional tumours are counted within those codes rather than as their own group.
Can GOJ cancer be cured?
It can be cured when it is found before it has spread and can be completely removed. Treatment combines chemotherapy or chemoradiotherapy with surgery in fit patients.
Which operation will I need?
Type I and II tumours usually need an oesophagectomy. Type III tumours usually need an extended gastrectomy. Your surgeon should explain which applies to you and why.
Does reflux cause it?
Long-standing reflux and Barrett's oesophagus raise the risk of type I and type II tumours. Most people with reflux never develop cancer, but changing symptoms should be checked.
This page is general information, not medical advice. It is written for people in Australia and does not replace a conversation with your own treating team, who know your history and your scans. If you are worried about a symptom, see your GP. In an emergency, call 000.
Sources: New England Journal of Medicine, ESOPEC trial, perioperative chemotherapy versus preoperative chemoradiotherapy in oesophageal cancer (2025), Cancer Research UK, Gastro oesophageal junction cancer, Cancer Australia, Oesophageal cancer statistics and symptoms, Cancer Council Australia, Oesophageal cancer, Cancer Council Australia, Optimal Care Pathway for people with oesophagogastric cancer, National Cancer Institute, Esophageal and Gastric Cancer Treatment (PDQ), NCCN Guidelines for Patients: Esophageal Cancer (2026), British Journal of Surgery, neoadjuvant chemoradiation versus chemotherapy for GOJ adenocarcinoma (2021).
Related guides.
Oesophageal cancer
Begins in the lining of the food pipe. The two main types are adenocarcinoma (often linked to long-standing reflux) and squamous cell carcinoma. Early changes can be subtle, such as difficulty swallowing or persistent heartburn.
Read the oesophageal cancer guideStomach (gastric) cancer
Begins in the stomach, most often in the inner lining. Symptoms such as indigestion, feeling full quickly or unexplained weight loss are easy to mistake for everyday complaints, which is why it is often found at a later stage.
Read the stomach cancer guideFund the work that finds it earlier.
Every dollar you give goes to a named project in gastro-oesophageal junction cancer research, surgical education or patient care, and every dollar is tracked.